Neurolief
PrivateLast Round
Convertible Debt
Mar 26, 2026
Total Funding Raised
$22.05M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Neurolief operates in Healthcare & Life Sciences and is based in Netanya. Its latest recorded funding round was a Convertible Debt round in March 2026.
Neurolief is a medical device company that develops non-invasive, wearable brain neuromodulation systems for the at-home treatment of neurological and neuropsychiatric disorders such as migraine and major depressive disorder.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Mental Health, Health IoT, Healthcare Analytics
Business Model
B2B2C
Customer Profile
Hardware Sales, Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Neurolief Comparables
Compare Neurolief with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Sooma | 84% | |
| Flow Neuroscience | 83% | |
| Theranica | 82% |
For institutional investors. Book with your work email.
Neurolief Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Convertible Debt | Mar 26, 2026 | ||||
| Convertible Debt | Aug 21, 2025 | ||||
| Strategic | Dec 28, 2023 | ||||
| Series A | May 9, 2018 | ||||
| Series A | Jun 1, 2017 | ||||
Seed | Jan 1, 2015 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Neurolief Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Champel Capital | Series A |
| Terralab Ventures | Series A, Seed |
| KT Squared | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 20, 2026
Open roles increased to 24, 80% of headcount.
- Mar 26, 2026
Raised $6M in early funding.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- signs_new_clientAug 11, 2026
On Aug 11th '26, Neurolief signs a new Department of Veterans Affairs contract with Veterans Affairs to bring Proliv Rx for major depressive disorder and Relivion MG for acute migraine to U.S. veterans, with multiple VA medical centers beginning to prescribe the therapies.
For institutional investors. Book with your work email.
Neurolief Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Neurolief's valuation, stock price, and market status.
Is Neurolief a public or private company?
Neurolief is a private company.
What is the current stock price of Neurolief?
Neurolief is a private company, so its shares have no public market price. Caplight tracks Neurolief's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Neurolief worth (valuation)?
Valuation information for Neurolief is not publicly available.
Can I buy Neurolief stock?
Neurolief shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Neurolief's last funding round?
Neurolief's most recent funding round was Convertible Debt on March 26, 2026.
Who are the main investors in Neurolief?
Key investors in Neurolief include Terralab Ventures.
Will Neurolief IPO soon?
No public IPO plans have been announced for Neurolief.
How can I track Neurolief secondary market activity?
Caplight tracks bids, offers, and trades in Neurolief's shares on secondary markets.